Tian Deying, Luo Chaojin, Zou Yuting
Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Sichuan, China.
Psychiatry Clin Psychopharmacol. 2025 Apr 16;35(2):111-116. doi: 10.5152/pcp.2025.24987. eCollection 2025 Jun.
This research is focused on evaluating the influence of administering cinepazide maleate and edaravone together on cerebral blood flow and neurofunctional markers in individuals who have recently suffered from an acute ischemic stroke (AIS).
Included in this retrospective investigation were 100 patients diagnosed with AIS and treated at our medical center between the period of December 2022 and December 2023. These individuals were subsequently segregated into 2 cohorts according to the different treatments they received, consisting of 50 patients each, referred to as the control group and the observation group. Upon admission, standard treatment was initiated for all patients, alongside additional edaravone therapy for the control group, and concurrent administration of cinepazide maleate and edaravone for the observation group, for a consecutive period of 14 days. The study involved the assessment of cerebral blood flow in the middle cerebral artery (MCA) and anterior cerebral artery (ACA), in addition to the evaluation of neurofunctional markers, serum inflammatory factors, activities of daily living (ADL) scores, and National Institutes of Health Stroke Scale (NIHSS) scores. Adverse reactions were closely monitored to determine the treatment's efficacy.
Subsequent to the treatment, augmented blood flow velocities were observed in both the MCA and ACA for both groups, particularly evident in the observation group. The observation group also demonstrated raised levels of nerve growth factor and lower levels of neuron-specific enolase and S100-β, with more notable differences when contrasted with the control group. Additionally, the observation group displayed reduced levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1, and elevated levels of interleukin-10 (IL-10), with more substantial variations as opposed to the control group. Furthermore, the observation group indicated enhanced ADL scores and diminished NIHSS scores, with more notable differences compared to the control group. The overall treatment effectiveness reached 94.00% in the observation group, markedly surpassing the 74.00% achieved in the control group.
The concurrent application of cinepazide maleate and edaravone yields notable effects on cerebral blood flow and contributes to the improvement of neurofunctional capabilities in individuals dealing with AIS.
本研究聚焦于评估联合使用马来酸桂哌齐特和依达拉奉对近期发生急性缺血性脑卒中（AIS）患者脑血流量和神经功能标志物的影响。
本回顾性研究纳入了2022年12月至2023年12月期间在我院接受治疗的100例诊断为AIS的患者。这些患者随后根据接受的不同治疗被分为2组，每组50例，分别称为对照组和观察组。入院后，所有患者均开始标准治疗，对照组在此基础上加用依达拉奉治疗，观察组同时给予马来酸桂哌齐特和依达拉奉，连续治疗14天。该研究包括评估大脑中动脉（MCA）和大脑前动脉（ACA）的脑血流量，以及评估神经功能标志物、血清炎症因子、日常生活活动（ADL）评分和美国国立卫生研究院卒中量表（NIHSS）评分。密切监测不良反应以确定治疗效果。
治疗后，两组患者的MCA和ACA血流速度均增加，在观察组尤为明显。观察组神经生长因子水平升高，神经元特异性烯醇化酶和S100-β水平降低，与对照组相比差异更显著。此外，观察组肿瘤坏死因子-α和单核细胞趋化蛋白-1水平降低，白细胞介素-10（IL-10）水平升高，与对照组相比差异更明显。此外，观察组ADL评分提高，NIHSS评分降低，与对照组相比差异更显著。观察组总治疗有效率达到94.00%，明显高于对照组的74.00%。
马来酸桂哌齐特和依达拉奉联合应用对脑血流量有显著影响，有助于改善AIS患者的神经功能。
